The upregulation of miR-142 and this molecular feedback mechanism also suggest that PMA and ATRA treatment could together provide sustainable levels of miR-142-3p to induce myeloid differentiation in APL through continued inhibition of CCNT2 and TAB2. This evidence concerns the gene TAB2 and acute promyelocytic leukemia.